Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
about
PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancerWhy post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapyPost-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies.Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials.Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.Clinical significance of post-progression survival in lung cancerSurrogate endpoints for overall survival in lung cancer trials: a review.Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression.Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression.Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.
P2860
Q27852105-6BFA5999-B5E7-4EC8-8024-B084369C910EQ30833179-DE6632F5-F670-40E7-9FCD-97DAC6905014Q33933021-E11D96FB-1AAB-4807-9034-0CE80B4DEF3FQ34866341-588E45B5-5115-462E-A2AB-9694EC92EAA3Q35164187-AE5483A4-AC65-42E0-AF61-3FBF907FF567Q36490413-1E0048D2-4BF6-46E2-B8AD-45464843DE20Q37329579-0D9D0EB1-B76D-4F11-BF31-74A760CD0EFCQ37389608-76ABD24A-FA7E-4C7C-A1FF-E81035F1A5D3Q37698439-2261ED09-B804-45A4-A485-205E3B02A871Q37706099-6C046DB9-BBF9-4EF7-9556-C2D179F498E3Q38062018-B450DDC9-54C2-4274-84EE-66E2FACEC27AQ38133562-F5478032-6FF2-4542-930F-2BB38E59A07FQ38390009-91FD9152-16F4-41BC-9398-00FBEA23DDF8Q38636718-FF654CEC-F8D3-4937-A270-B2CE380D707DQ38669447-53304920-BB22-4B82-AB56-3CA201F28691Q38841987-5905DC2A-3B32-443B-B1A3-90B8E4DDB485Q38852314-75D824B8-F6CB-4071-A57B-9F85583F6141Q39150005-E3B32C04-5A53-4161-9E6F-914520D90F39Q39572955-7A8F0F5B-1A5E-4ABF-AAA0-2502FF91FF03Q40461237-01564CA2-CCB9-498D-AB7D-22BFBCBCB775Q40955279-6AFF23ED-20AE-4C52-87E8-4AF8CC9AEF80Q43654035-145E91F2-DE15-480F-BB6E-700BB1AD7DC9Q44365458-3B7C6396-E259-41A8-88B7-82F14E2FDA84Q47189344-C2F30AC7-EA4F-4853-9E48-F71706ACFB7BQ50632474-690961A5-A740-46FE-95A2-8538B06CCBEBQ50877426-A88AC11B-5A40-4C21-9DDF-09BE9FBA2DCCQ51088833-34F5D5B2-D6BA-4207-83E9-634A7B9A040BQ53717818-C6FBB8D5-61A4-49D5-BCD0-4A45386C0E80Q54951150-0F67D40C-E8AC-4C4A-87AB-B0530FEB5364
P2860
Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Postprogression survival for f ...... ced non-small-cell lung cancer
@ast
Postprogression survival for f ...... ced non-small-cell lung cancer
@en
Postprogression survival for f ...... ced non-small-cell lung cancer
@nl
type
label
Postprogression survival for f ...... ced non-small-cell lung cancer
@ast
Postprogression survival for f ...... ced non-small-cell lung cancer
@en
Postprogression survival for f ...... ced non-small-cell lung cancer
@nl
prefLabel
Postprogression survival for f ...... ced non-small-cell lung cancer
@ast
Postprogression survival for f ...... ced non-small-cell lung cancer
@en
Postprogression survival for f ...... ced non-small-cell lung cancer
@nl
P2093
P2860
P3181
P356
P1433
P1476
Postprogression survival for f ...... ced non-small-cell lung cancer
@en
P2093
H. Hayashi
I. Okamoto
K. Nakagawa
P2860
P304
P3181
P356
10.1093/ANNONC/MDR487
P407
P577
2012-06-01T00:00:00Z